

This article was downloaded by:

On: 30 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713618290>

The Chemistry of 4-Substituted Oxazaphosphorinanes (OAP) (Tools for Cancer Research and Therapy)

Ulf Niemeyer^a; Jürgen Engel^a; Gerhard Scheffler^a; Jörg Pohl^a; Gerhard Hägele^b; Bernt Krebs^c

^a Asta-Werke AG Degussa Pharma Gruppe, Bielefeld, F. R. Germany ^b Inst. Anorg. u. Strukturchemie I Univ., Düsseldorf, F. R. Germany ^c Anorg. Chem. Inst. Univ., Münster, F. R. Germany

To cite this Article Niemeyer, Ulf , Engel, Jürgen , Scheffler, Gerhard , Pohl, Jörg , Hägele, Gerhard and Krebs, Bernt(1987) 'The Chemistry of 4-Substituted Oxazaphosphorinanes (OAP) (Tools for Cancer Research and Therapy)', Phosphorus, Sulfur, and Silicon and the Related Elements, 30: 3, 585 — 588

To link to this Article: DOI: 10.1080/03086648708079133

URL: <http://dx.doi.org/10.1080/03086648708079133>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

THE CHEMISTRY OF 4-SUBSTITUTED OXAZAPHOSPHORINANES (OAP) (TOOLS FOR CANCER RESEARCH AND THERAPY)

ULF NIEMEYER¹, JÜRGEN ENGEL¹, GERHARD SCHEFFLER¹,
JÖRG POHL¹, GERHARD HÄGELE², BERNT KREBS³

1) Asta-Werke AG Degussa Pharma Gruppe, D-4800 Bielefeld 14

2) Inst. Anorg. u. Strukturchemie I Univ. D-4000 Düsseldorf

3) Anorg. Chem. Inst. Univ. D-4400 Münster, F.R. Germany

Abstract Novel chemical approaches resulted in 4-substituted OAP derivatives, linked by a sulfur, oxygen or nitrogen atom to C-4. The cis- and trans-epimers were stereoselectively synthesized from the key intermediate 4-hydroxycyclophosphamide. An alternative route will be presented. The stereochemistry of 4-substituted OAP are confirmed by single crystal X-ray analysis and by NMR-spectra for more than 50 compounds. The connectivities of the nuclei observed in the homonuclear and heteronuclear COSY plots are summarized with data. In aqueous solution 4-substituted OAP are hydrolyzed with a half-life at physiological conditions of a few minutes for S-derivatives and of about 20 hours for the more stable N-derivatives. The pH-dependance of the hydrolysis rates including epimerisation and transthiioacetalisation are submitted. Pharmacokinetical and biological activity data are presented.

INTRODUCTION

Clinical and toxicological observations on mustard-gas initiated the development of DNA-alkylating drugs against cancer. Cyclophosphamide (CP, Endoxan^R), the most widely used drug of today, was synthesized in 1956¹. In this compound the original sulfur atom of mustard-gas was exchanged by one nitrogen of a cyclic phosphorodiamidic ester of the OAP type. Physiologically, the first metabolic event is the oxidation of CP by hepatic enzymes to 4-hydroxy-CP. Former approaches to utilize free 4-hydroxy-CP for clinical trials involved the synthesis of 4-substituted OAP^{2,3}.

SYNTHESIS

The initial step is ozonisation of O-3-butenyl-N,N-bis-(2-chloro-ethyl)-phosphorodiamidate or of CP yielding in 4-hydroperoxy-CP, which is stable at -20°C . Reduction under mild conditions by triphenyl-phosphine or by aqueous sodium thiosulfate leads to 4-hydroxy-CP. 4-Hydroxy-CP is a cyclic half-animale which reacts with nucleophiles according to the equation:



where X might be oxygen, sulfur or nitrogen.

Up to 1977 only 4-hydroperoxy-CP and some thio-derivatives ($\text{X} = \text{S}$) were characterized by us and others^{2,3}. Recently an acid-catalysed reaction of 4-hydroxy-CP with hydroxyurea yielded in 4-hydroxyureido-CP. It was the first compound in which a radical is linked at the OAP-ring in the 4-position by a nitrogen. As both the carbon 4 and the phosphorus are chiral, we synthesized stereoselectively the two racemic diastereomers. Following the general strategy of Fig. 1, more than 50 of 4-N-derivatives were synthesized.




FIGURE 1 Synthesis of 4-substituted OAP

Novel O-connected derivatives were synthesized by reaction of 4-hydroxy-CP with N-hydroxy-N,N'-dimethylurea and N-hydroxyurethane. Urotoxic 4-hydroxy-CP is detoxified in the urine by a reaction with mesna to 4-sulfonato-ethylthio-CP⁴. Synthetically this reaction in aqueous acetone leads stereoselectively to the crystalline cis-isomer (mafosfamide) as a cyclohexylammonium salt in more than 80 % yield⁵. For clinical studies the less toxic mafosfamide L-lysine salt was prepared on a strong acid resin column.

STEREOCHEMISTRY

The stereochemistry of mafosfamide was confirmed by single-crystal X-ray diffraction. The phosphoryl oxygen and the sulfonatoethylthio side-chain are approximately cis-diaxially corresponding to the cis-isomer of 4-hydroxy-CP. The axial preference of the sulfonatoethylthio side-chain is attributed to an anomeric effect. Only one antipode was found in the crystal lattice. This separation of antipodes by crystallization is a specific phenomenon in the OAP field. The X-ray analysis of 4-hydroxyureido-CP established the relative configuration as trans.

The stereochemistry in solution cannot be elucidated by a single NMR-spectrum. However, based on two X-ray analyses semi-empirical rules could be derived, which proved to be conclusive for more than 50 CP-compounds. By high-field NMR using 2D experiments including the phosphorus-decoupled H,H-COSY-technique all questions concerning spin-assignment and molecular structure in solution state could be answered⁶. Low and high temperature NMR showed clearly that only one conformation is preferred in solution.

BEHAVIOUR IN SOLUTION

In aqueous solution, 4-substituted OAP are hydrolyzed, leaving

the corresponding thiol, hydroxyurea or hydroxyurethane and 4-hydroxy-CP. The half-life in solution of the S- and O-derivatives are a few minutes and of the N-derivatives about 20 hours at pH 7, 37° C, with a pH optimum of minimal hydrolysis. For S-derivatives, i.e. mafosfamide, the greatest stability is observed around pH 4. Out of this range the stability decreases exponentially. The N-derivatives are most stable at pH 7.

BIOLOGICAL ACTIVITY

All new OAP are highly cytotoxic agents. The different behaviour in solution, however, affects the pharmacokinetics and the biological availability. S- and O-derivatives are more toxic (LD 50: 150 - 350 mg/kg) in rats and mice than N-derivatives (LD 50: >1,000 mg/kg). In vitro the S- and O-compounds are found to be more active. The curative effectivity in vivo, however, against rat-tumors is nearly equal for all derivatives.

REFERENCES

1. N. Brock, in Structure-activity relationships of anti-tumor agents, edited by D. N. Reinholdt, T.A. Connors, H.M. Pinedo and K.W. van de Poll, Developments in Pharmacology, 3, (Martinus Nijhoff Publ., The Hague, Boston, London, 1983) p. 239.
2. A. Takamizawa, S. Matsumoto, T. Iwata, K. Kentagiri, Y. Tochino and K. Yamaguchi, J. Amer. Chem. Soc., 95, 985 (1973).
3. G. Peter, T. Wagner and H.-J. Hohorst, Cancer Treat. Rep., 60, 429 (1976)
4. N. Brock, J. Stekar, J. Pohl, U. Niemeyer and G. Scheffler, Arzneim.-Forsch./Drug Res., 29, 659 (1979).
5. U. Niemeyer, J. Engel, G. Scheffler, K. Molge, D. Sauerbier and W. Weigert, Invest. New Drugs, 2, 133 (1984).
6. G. Hägele, J. Seega, W. Kücklhaus, J. Engel and U. Niemeyer, Magnetic Resonance in Chemistry, in press (1986).

Acknowledgement: We wish to thank the Bundesministerium für Forschung und Technologie, Bonn, and the Fonds der Chem. Industrie for partial financial support.